Newsletter N. 1 View online
FlaviVaccine
Safely protecting against mosquito-borne viral diseases

Welcome to the first edition of the FLAVIVACCINE newsletter!

FLAVIVACCINE is a European innovation project co-funded by the European Union to develop a single vaccine candidate against multiple flaviviruses, including Dengue, Yellow Fever, Zika, and West Nile. The project began in January 2024 and will run until December 2027.

FLAVIVACCINE aims to enhance the EU’s preparedness and response to future epidemic and pandemic threats by delivering a safe and effective vaccine.

With our annual newsletter, we will keep you updated on the project’s progress, as well as relevant news and articles.

In this first issue:

  • FLAVIVACCINE General Assembly in Madrid: A key event for discussing research advancements, dissemination activities, and strategic planning.
  • One scientific paper co-authored by FLAVIVACCINE coordinator Julien Pompon, exploring how West Nile virus can spread through mosquito excreta.

 

Preprint available
  • One scientific paper about challenges, effectiveness, safety, and the pros and cons of various administration routes, such as intramuscular, transdermal, oral, and nasal delivery.
Scientific paper
  • Watch our FLAVIVACCINE presentation video and download the project flyer.

We hope you enjoy our newsletter!

Best regards,
The FLAVIVACCINE Team

About FLAVIVACCINE

Click on the images to learn more:

The project and its aim
Market potential
The Flaviviruses
Project highlights
FLAVIVACCINE project holds successful General Assembly meeting
March 13, 2025
On March 11-12, the FLAVIVACCINE consortium gathered for its biannual General Assembly meeting, bringing together partners from across the project to review progress and outline the next steps.
Read more...
Scientific papers from the consortium

West Nile virus can spread through mosquito excreta, potentially infecting larvae and sustaining the virus in mosquito populations. 

Preprint available
Scientific papers and articles from external sources

Vaccines can be administered in various ways, each influencing the release speed, immune response, and side effects.

Injected vaccines are the most common, with methods like intramuscular (into muscle), subcutaneous (into fat), and intradermal (into the skin), each offering distinct benefits for vaccine delivery and immune activation. But there are many others like intravenous, oral vaccines and intranasal. Each method offers unique advantages for different needs and settings.

A scientific paper published in Vaccine: X, the open-access companion journal to Vaccine, and an article by Gavi, the Vaccine Alliance, that spreads the availability of news, features, and explainers from every corner of global health and immunization.

Below, you can find both.

 

Scientific paper
Article
Presentation video
Flavivaccine flyer

Click below to download the flyer with clear information and a QR code for the website.

Download the flyer
image
Co-funded by the European Union. The views and opinions expressed are those of the author(s) only and do not necessarily reflect those of the European Union or HADEA. Neither the European Union nor the granting authority can be held responsible for them.
FlaviVaccine
Safely protecting against mosquito-borne viral diseases
linkedin  youtube  bluesky 
Unsubscribe   |   Manage your subscription   |   View online
FlaviVaccine